EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 4

Ensembl ID : ENSPKIG00000012954
Gene Symbol: PSMD4
3 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSPKIG00000024819
Gene Symbol: PSMD6
4 Cross references
139 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSPKIG00000023314
Gene Symbol: PSMD6
3 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSPKIG00000001844
Gene Symbol: PSMD7
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSPKIG00000013294
Gene Symbol: PSMD8
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-2-Like

Ensembl ID : ENSPKIG00000024738
Gene Symbol: LOC111852026
3 Cross references
69 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSPKIG00000010142
Gene Symbol: PSMB11
3 Cross references
168 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSPKIG00000010120
Gene Symbol: LOC111854587
3 Cross references
208 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSPKIG00000015339
Gene Symbol: LOC111857157
4 Cross references
146 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSPKIG00000012420
Gene Symbol: LOC111842809
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSPKIG00000019279
Gene Symbol: LOC111835645
3 Cross references
220 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSPKIG00000009886
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).